Lurasidone dihydrochloride is an atypical antipsychotic medication within the benzisothiazole class, primarily indicated for the treatment of schizophrenia and acute depressive, manic, or mixed episodes… Read more
Lurasidone dihydrochloride is an atypical antipsychotic medication within the benzisothiazole class, primarily indicated for the treatment of schizophrenia and acute depressive, manic, or mixed episodes associated with bipolar I disorder. As a therapeutic agent, it functions by antagonizing serotonin 5-HT2A and dopamine D2 receptors to regulate neurotransmitter activity in the central nervous system. This category of compounds includes Lurasidone dihydrochloride reference standards, alongside its pharmacopeial and non-pharmacopeial impurities, metabolites, and stable isotope-labelled derivatives. Pharmaceutical laboratories rely on these high-quality analytical materials for impurity profiling, method validation, and rigorous quality control protocols. By utilizing these precise standards, researchers and analytical chemists can ensure the accuracy of assays, confirm the identification of degradation products, and maintain the integrity of pharmaceutical formulations throughout the development and manufacturing lifecycle.